类风湿关节炎患者COVID-19风险:美国退伍军人事务部匹配队列研究
多变量Cox模型显示,RA与COVID-19风险升高(校正HR 1.25,95%CI 1.13-1.39)及COVID-19住院或死亡风险升高(校正HR 1.35,95%CI 1.10-1.66)相关。
要点
- RA患者较非RA对照的COVID-19风险升高(校正HR 1.25,95%CI 1.13-1.39)。
- RA患者COVID-19住院或死亡风险亦升高(校正HR 1.35,95%CI 1.10-1.66)。
- 使用DMARDs和泼尼松与COVID-19及重症风险相关,RA自身抗体血清阳性不相关。
核心结论
- RA患者较非RA对照发生COVID-19及重症COVID-19(导致住院或死亡)的风险更高。
研究设计与样本
- 采用美国退伍军人事务部全国数据的匹配队列研究,RA患者与非RA对照按年龄、性别和VA站点1:1匹配,每组33,886人。
主要发现
- 随访期间队列中1,503例诊断为COVID-19,其中388例为重症COVID-19(住院或死亡),228例死亡与COVID-19无关。
- 多变量模型中,RA与COVID-19风险升高相关(校正HR 1.25,95%CI 1.13-1.39)。
- RA与COVID-19住院或死亡风险升高相关(校正HR 1.35,95%CI 1.10-1.66)。
- 使用改善病情抗风湿药(DMARDs)和泼尼松、自报黑人种族、自报西班牙裔 ethnicity 及存在多种慢性病各自与COVID-19和重症COVID-19风险相关。
- RA自身抗体血清阳性与COVID-19或重症COVID-19风险不相关。
关键数值与推荐
- 重症COVID-19定义为需要住院或导致死亡。
临床怎么用
- 鉴于RA患者COVID-19风险接近其他公认慢性病,应考虑将RA患者优先纳入COVID-19预防和管理策略。
局限性
- 队列以男性为主(84.5%),平均年龄67.8岁,可能限制对其他人群的推广。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Rheumatoid arthritis (RA) and its treatments are associated with an increased risk of infection, but it remains unclear whether these factors have an impact on the risk or severity of COVID-19. The present study was undertaken to assess the risk and severity of COVID-19 in a US Department of Veterans Affairs (VA) cohort of patients with RA and those without RA. METHODS: A matched cohort study using national VA data was conducted. Patients diagnosed as having RA were identified among nondeceased individuals who were active in the VA health care system as of January 1, 2020 and who had received care in a VA medical center in 2019; patients for whom no RA diagnostic code was indicated were matched to the RA patients (1:1) by age, sex, and VA site (non-RA controls). Patients diagnosed as having COVID-19 and those with severe COVID-19 (defined as requiring hospitalization or leading to death) were ascertained from a national VA COVID-19 surveillance database through December 10, 2020. Multivariable Cox models were used to compare the risk of COVID-19 and COVID-19 hospitalization or death between RA patients and non-RA controls, after adjusting for demographic characteristics, comorbidities, health care utilization and access, and county-level COVID-19 incidence rates. RESULTS: This VA cohort of RA patients and non-RA controls (n = 33,886 subjects per group) predominantly comprised male patients (84.5%), and the mean age was 67.8 years. During follow-up, 1,503 patients in the cohort were diagnosed as having COVID-19; among them, 388 patients had severe COVID-19 (hospitalization or death), while in 228 patients, the deaths were not related to COVID-19. In the multivariable model, RA was associated with a higher risk of COVID-19 (adjusted hazard ratio [HR] 1.25 [95% confidence interval (95% CI) 1.13-1.39]) and a higher risk of COVID-19 hospitalization or death (adjusted HR 1.35 [95% CI 1.10-1.66]) as compared to non-RA controls. Use of disease-modifying antirheumatic drugs and prednisone, as well as self-reported Black race, self-reported Hispanic ethnicity, and presence of several chronic conditions, but not seropositivity for RA autoantibodies, were each associated with risk of COVID-19 and severe COVID-19 (hospitalization or death). CONCLUSION: Patients with RA are at higher risk of developing COVID-19 and severe COVID-19 (leading to hospitalization or death) compared to those without RA. With a risk of COVID-19 that approaches that of other recognized chronic conditions, these findings suggest that RA patients should be prioritized for COVID-19 prevention and management strategies.
引用
- England BR, Roul P, Yang Y, et al. Risk of COVID-19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At-Risk Individuals. Arthritis Rheumatol. 2021. PMID: 33955209. doi:10.1002/art.41800
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。